Top Ten most popular articles on Pharmafile.com this week
pharmafile | February 16, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Alzheimer's disease, Roche, Top 10 news, Top ten news, Trump, biotech, drugs, pharma, pharmaceutical
Another week is finished and it’s been a disastrous one for research into a potential treatment for Alzheimer’s disease. Two of our top ten stories are, unfortunately, regarding the failure of late-stage candidates for treatment that have been dropped and another where one of the most promising candidates has investors fearing that it, too, may be a dud. Here’s to hoping next week’s brings brighter news.
Check out the week’s ten most popular articles on Pharmafile.com now!
10. New biotech facility to bring 350 jobs to Dublin
MSD announced plans to invest in a new biotechnology facility in Dublin, which it claims will create 350 jobs in the Irish capital.
9. NICE backtracks to recommend Roche’s Gazyvaro in follicular lymphoma
Reversing its decision to reject the drug, NICE issued its final decision to recommend the use of Roche’s Gazyvaro on the NHS.
8. Trump’s drug pricing reforms lack bite
President Trump’s rhetoric leading up to his election had the pharmaceutical industry very worried but reforms to drug pricing published this week look like those fears were unfounded.
7. Boehringer terminates Alzheimer’s candidate after Phase 2 failure
Boehringer Ingelheim announced that it has halted development of its candidate BI 409306 in the treatment of Alzheimer’s, after it failed to hit its primary endpoints in Phase 2 studies.
6. New flu med can destroy influenza virus in one day
Researchers in Japan have achieved a notable success in a Phase 3 clinical trial to determine whether a new vaccine could be more effective than current treatments options in treating flu.
5. Biogen shares hit by key Alzheimer’s drug concerns
Biogen made investors very nervous after it announced that it was choosing to add an additional 510 patients to its key trial into its Alzheimer’s medicine.
4. Taking a look behind the scenes of Serialisation
Our latest feature looking at the process of implementing serialisation a year ahead of the European deadline.
3. Sanofi in $155m influenza vaccine deal
Sanofi revealed that it agreed a deal with SK Chemicals, a South Korean vaccine manufacturer, to license its cell culture technology in a $155 million deal.
2. MSD shuts down Phase 3 trial in Alzheimer’s
MSD has halted development of the drug Verubecestat after it could not present enough potential efficacy in prodromal forms of the condition to warrant further study.
1. Pfizer taps real world evidence for CVD in new partnership
BC Platforms, a company that focuses on genomic data managements and analysis, has announced that it has partnered with Pfizer to generate real world evidence in atrial fibrillation patients
Related Content
Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech
Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed …
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
